Mylan had received a major boost with the FDA approval for a generic version of Copaxone 40mg. The company has more than 30 submissions planned in 2018. However, the generic business in the United States continues to experience pricing pressure. Although volatility in the markets is expected to continue in 2018, yet these new approvals should position Mylan better in the year ahead and help it combat the decline in EpiPen sales which is also facing supply constraint issues.